| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.00741-11 |
| P8608 | Fatcat ID | release_7yaiq3ohf5b65lc6rjixxgestu |
| P932 | PMC publication ID | 3232796 |
| P698 | PubMed publication ID | 21947390 |
| P5875 | ResearchGate publication ID | 51674454 |
| P50 | author | Max von Kleist | Q42704607 |
| P2093 | author name string | C Schütte | |
| M Frank | |||
| A Kunz | |||
| C Kloft | |||
| G Harms | |||
| P2860 | cites work | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 |
| Drug-class specific impact of antivirals on the reproductive capacity of HIV | Q28473451 | ||
| Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial | Q28476329 | ||
| HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time | Q29547822 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. | Q30326359 | ||
| Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. | Q33364134 | ||
| Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants | Q33396950 | ||
| HIV transmission through breastfeeding: a study in Malawi | Q43460592 | ||
| Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. | Q44109299 | ||
| Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity | Q44495120 | ||
| Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial | Q44625140 | ||
| Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay | Q44668486 | ||
| Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. | Q45285923 | ||
| Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team | Q45754372 | ||
| Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine | Q46159074 | ||
| Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial | Q46401720 | ||
| Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission | Q46558677 | ||
| Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. | Q46806431 | ||
| A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc | Q46830659 | ||
| Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire | Q46902929 | ||
| The probability of HIV infection in a new host and its reduction with microbicides. | Q51887514 | ||
| A stochastic model for early HIV-1 population dynamics. | Q52230372 | ||
| Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial | Q64131584 | ||
| Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial | Q33873955 | ||
| Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy | Q34332659 | ||
| Antiretroviral regimens in pregnancy and breast-feeding in Botswana | Q34395082 | ||
| Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates | Q34483505 | ||
| Antiretroviral treatment for children with peripartum nevirapine exposure | Q34494986 | ||
| Modelling viral and immune system dynamics | Q34572224 | ||
| A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo | Q34858885 | ||
| Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance | Q34937254 | ||
| Breast-feeding and Transmission of HIV-1. | Q35628427 | ||
| Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals | Q35804046 | ||
| Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients | Q35872364 | ||
| Maternal or infant antiretroviral drugs to reduce HIV-1 transmission | Q36231035 | ||
| Updates to the World Health Organization's Recommendations for the Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants | Q36503025 | ||
| Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle | Q36534260 | ||
| Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review | Q36738171 | ||
| Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis | Q36833511 | ||
| HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. | Q37090735 | ||
| Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs | Q37345610 | ||
| Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine | Q37351379 | ||
| Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients | Q37598731 | ||
| Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count | Q38870802 | ||
| Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration | Q38875383 | ||
| Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials | Q38875948 | ||
| Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. | Q38882753 | ||
| Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial | Q38884501 | ||
| Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). | Q38884920 | ||
| Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. | Q38885782 | ||
| A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). | Q38886823 | ||
| Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial | Q38967453 | ||
| Response to antiretroviral therapy after a single, peripartum dose of nevirapine | Q40799526 | ||
| Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells | Q40976774 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| HIV transmission | Q49029021 | ||
| P304 | page(s) | 5529-5540 | |
| P577 | publication date | 2011-09-26 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes | |
| P478 | volume | 55 |
| Q34528801 | Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis |
| Q28546418 | Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique |
| Q28481233 | Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission |
| Q55299659 | Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. |
| Q28486262 | In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis |
| Q64235564 | Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis |
| Q37126494 | Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1. |
| Q28547109 | Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings |
| Q28481276 | Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection |
| Q34922985 | Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants |
| Q64098099 | The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis |
Search more.